FierceBiotech

Press Release: DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial CAMBRIDGE, Mass. - Apr 12, 2007 - Dyax Corp. announced today positive topline results from its Phase 3, ...
FierceBiotech

FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Advisory Committee voted (6 yes, 5 no, 2 abstentions) ...
Reuters

Dyax and Genzyme announce agreement to terminate joint venture for the commercialization of DX-88 in HAE

Co announces it has reached a mutual agreement with Genzyme (GENZ) to terminate their joint venture for the development and commercialization of DX-88 for hereditary angioedema. The termination ...
BioWorld

Dyax Gets Boost From Positive Phase III Data Of DX-88 In HAE

Immunotherapy-based cancer vaccines could permanently kill tumors by stimulating immune cells in multiple ways. At the 27th Annual Meeting of the American Society... The U.S. FDA issued a May 9 ...
Business Wire

Dyax Announces DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA4 ®)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 ...